Joseph P. Lyssikatos - 20 Jan 2026 Form 4 Insider Report for Enliven Therapeutics, Inc. (ELVN)

Role
CHIEF SCIENTIFIC OFFICER
Signature
/s/ Ben Hohl, by power of attorney
Issuer symbol
ELVN
Transactions as of
20 Jan 2026
Net transactions value
-$535,099
Form type
4
Filing time
22 Jan 2026, 17:34:48 UTC
Previous filing
12 Jan 2026
Next filing
10 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER C/O ENLIVEN THERAPEUTICS, INC., 6200 LOOKOUT ROAD, BOULDER /s/ Ben Hohl, by power of attorney 22 Jan 2026 0001967150

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ELVN Common Stock Sale $144,814 -5,491 -0.72% $26.37 759,697 20 Jan 2026 See footnote F1, F2, F3
transaction ELVN Common Stock Sale $390,285 -14,509 -1.9% $26.90 745,188 20 Jan 2026 See footnote F1, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024.
F2 This transaction was executed in multiple trades at prices ranging from $25.605 to $26.5928. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F3 The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee.
F4 This transaction was executed in multiple trades at prices ranging from $26.6137 to $27.344. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.